Opinion|Videos|August 5, 2024
Dr Hanna & Hope Rugo, MD Shares Potential Role of Improving Access to CDK4/6 Inhibitors
Drs. Hanna and Rugo discuss possible access improvements in regards to CDK4/6 inhibitors.
Advertisement
Video content above is prompted by the following question(s):
- What is the potential role of value-based pricing models or alternative payment arrangements in improving access to CDK4/6 inhibitors for eligible patients?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
AAP Breaks With CDC, Maintains Broader 2026 Childhood and Adolescent Vaccine Schedule
2
Experts Warn CDC Childhood Immunization Schedule Revisions Could Reduce Uptake, Erode Public Trust
3
New Dermatologic Therapies Make Waves at Maui Derm 2026
4
Trulicity, Botox Headline Drugs Included in the Third Cycle of Medicare Price Negotiations
5
